scholarly journals EFFICACY OF SOFOSBUVIR AND RIBAVIRIN BASED TREATMENT IN CHRONIC HEPATITIS C GENOTYPE 3 PATIENTS

2020 ◽  
Vol 4 (2) ◽  
Author(s):  
Mushtaq Laway ◽  
Shabir Shiekh ◽  
Shafat Sideeq ◽  
Zafar Wani ◽  
Peerzada Mohd Shafi
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Side Effects ◽  
Chronic Hepatitis C ◽  
Virological Response ◽  
Cure Rate ◽  
Genotype 3 ◽  
Treatment Naïve ◽  
Cirrhotic Patients

Introduction: Hepatitis C virus (HCV) infection represents a major healthcare challenge in both industrialized and developing countries. The standard treatment for hepatitis C virus (HCV) infection has been interferon-based over many years with less than satisfactory cure rate and many side-effects. Directly acting antivirals (DAAs) have promise for a treatment regimen free of interferons with much better cure rate and minimal side-effects. Aims and Objectives: To evaluate efficacy and safety of an oral interferon-free regimen, sofosbuvir plus ribavirin in the treatment in genotype 3 chronic hepatitis C patients. Materials and Methods: 200 treatment naïve chronic hepatitis C genotype 3 patients of either sex with age more than 18 years were enrolled in the study. Sofosbuvir 400 mg once daily plus Ribavarin weight-based was given to all the patients. Duration of treatment was 24 weeks and 12 weeks to cirrhotics and non-cirrhotics respectively. Data analysis was performed using the IBM SPSS version 22. Results and Observations: In this prospective study the total number of patients was two hundred (n=200). The mean age (in years) of patients was 44.2 ± 14.7. The number of male patients was 112 (56 %) and 88   (44 %) were females. The number of cirrhotic patients was 70 while 130 were non-cirrhotic. On comparison on the basis of sustained virological response at twelve weeks of the completion of treatment (SVR12) we observed that treatment naïve cirrhotic patients had  SVR 12 of  92.8 %  while in the non cirrhotic patients SVR 12= was 96.9 % . Adverse effects were insignificant and none of the patients dropped out because of side effects. Conclusion: The sofosbuvir and ribavirin based therapy showed very good rates of sustained virological response in chronic hepatitis C genotype 3 patients irrespective of the state of fibrosis. In addition it was found to be cost effective, safe and very well-tolerated. Keywords: Hepatitis C; Genotype 3; directly acting antivirals, Sofosbuvir, Sutained virologic response (SVR).

scholarly journals EFFICACY OF SOFOSBUVIR PLUS VALPATASVIR BASED THERAPY IN THE TREATMENT OF TREATMENT NAIVE CHRONIC HEPATITIS C GENOTYPE-3 IN KASHMIR.

2020 ◽  
Vol 4 (4) ◽  
Author(s):  
Shabir Shiekh ◽  
Shafat Lone ◽  
Zafar Wani ◽  
Zafar Kawoosa ◽  
Showkat A. Kadla
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Sustained Virological Response ◽  
Chronic Hepatitis C ◽  
Virological Response ◽  
Fixed Dose ◽  
Direct Acting Antivirals ◽  
Genotype 3 ◽  
Treatment Naïve ◽  
Direct Acting

Abstracts Objectives: Direct acting antivirals (DAAs) have dramatically changed our approach towards management of chronic hepatitis C by yielding a high sustained virological response (SVR). Genotype-3 is the most common genotype found in Kashmir (Northern India) besides having an aggressive nature with increased risk of steatosis and hepatocellular carcinoma. We assessed the efficacy and safety of sofosbuvir plus valpatasvir based therapy in chronic hepatitis C genotype-3 infection in Kashmiri population. Aims and objectives: An observational, prospective, open label, hospital based study was carried over a period of two years which included 230 treatment naïve chronic hepatitis-C genotype-3 patients. Patients were divided in two groups. Group-A: Non-cirrhotics who received sofosbuvir (400 mg daily) with valpatasvir (100 mg) in fixed–dose combination for 12 weeks. Group B included CPT class A cirrhotics who received sofosbuvir (400mg daily) with valpatasvir (100 mg daily) and weight based ribavarin for 12 weeks. The primary end point was a sustained virologic response at 12 weeks after the end of therapy. Results and observations: We observed 98.57 % (138/140) SVR 12 in non-cirrhotics who received valpatasvir plus sofosbuvir treatment regimen. Cirrhotics who received Sofosbuvir plus valpatasvir with ribavirin observed SVR of 96.6 % (87/90). All patients tolerated the drug regimens well without any serious adverse effect. Conclusion: Once daily oral Sofosbuvir plus valpatasvir based fixed dose rerimen is highly efficient and safe in treatment of both cirrhotics and non-cirrhotic hepatitis C patients. Keywords: Direct acting antivirals; sustained virological response; Genotype; chronic hepatitis C

EFFICACY OF SOFOSBUVIR AND DACLATASVIR IN COMPENSATED CHRONIC HEPATITIS C INFECTION: A SINGLE CENTER, OPEN-LABEL AND PROOF OF CONCEPT STUDY

2021 ◽  
pp. 27-30
Author(s):  
Manisha Thakur ◽  
Anurag Chauhan ◽  
Prashant Jambunathan ◽  
Shikha Awasthi ◽  
Thilagavathi K ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Sustained Virological Response ◽  
Chronic Hepatitis C ◽  
Virological Response ◽  
Sustained Viral Response ◽  
Hcv Rna ◽  
Hepatitis C Infection ◽  
Genotype 3 ◽  
Treatment Naïve

AIMS AND OBJECTIVES: The advent of directly acting agents for the treatment of Hepatitis C infection has forever transformed our understanding and management of viral infections. With over 95 % patients achieving a sustained viral response at 12 weeks with some of these newly inducted agents, the prospect of eradicating the Hepatitis C virus seems like an achievable target, which makes this one of the most important discoveries in modern medicine. We studied the combination of Sofosbuvir and Daclatasvir in patients with chronic hepatitis C infection (Genotype 3) to assess the rates of sustained virological response at 12 weeks. We studied 67 treatment naive METHODS: patients with compensated chronic hepatitis C infection (genotype 3). They were all started on Tab Sofosbuvir 400 mg daily and Tab Daclatasvir 60 mg once daily for 12 weeks and followed up for a total of 24 weeks, which includes a treatment duration and observation period of 12 weeks each. The patients were monitored with HCV RNA levels at one, three and six months, with as many evaluations of liver function and routine hemogram. Our results show that 70.5% (p<0.05) achieved a rapid vi RESULTS: rological response, 88.5% (p<0.05) achieved an end of treatment response and, similarly, an impressive 88.05% (p<0.05) showed a sustained virological response at the end of 12 weeks. One patient who developed a psoriasiform rash discontinued the medication and was excluded from the analysis, as duration of treatment had not been completed. No major dose related adverse events were reported. Sofosbuvir and Daclatasvir is an acceptable, well tolerated regimen for treatment naive, CONCLUSIONS: compensated patients with genotype 3 infection. Based on our observations and data, we recommend this as the rst line DAA for patient with compensated genotype 3 infection until medications with higher SVR 12 are available in the Indian market.

Impact of IL28B-genotype on virological response in treatment-naive Austrian patients with chronic hepatitis C

2010 ◽  
Vol 48 (05) ◽  
Author(s):  
A Staettermayer ◽  
K Rutter ◽  
S Beinhardt ◽  
TM Scherzer ◽  
K Zinober ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Virological Response ◽  
Il28b Genotype ◽  
Treatment Naïve

scholarly journals NS3 Variability in Hepatitis C Virus Genotype 1A Isolates from Liver Tissue and Serum Samples of Treatment-Naïve Patients with Chronic Hepatitis C

Intervirology ◽  
2018 ◽  
Vol 61 (1) ◽  
pp. 1-8
Author(s):  
Deborah D’Aliberti ◽  
Irene Cacciola ◽  
Cristina Musolino ◽  
Giuseppina Raffa ◽  
Roberto Filomia ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Liver Tissue ◽  
Serum Samples ◽  
Virus Genotype ◽  
Genotype 1A ◽  
Treatment Naïve

scholarly journals Distribution of hepatitis C virus genotypes and subtypes in a group of patients with chronic hepatitis C from Canton Sarajevo, 2012-2018

2019 ◽  
Vol 49 ◽  
Author(s):  
Irma Salimović- Bešić ◽  
Adna Kahriman ◽  
Suzana Arapčić ◽  
Amela Dedeić- Ljubović
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Hcv Rna ◽  
Genotype 3 ◽  
Hcv Genotype ◽  
Hcv Genotypes ◽  
Number Of Patients ◽  
Subtype 1B

Background: Hepatitis C virus (HCV) genotypes and subtypes exhibit significant geographic variations.Aim: To analyse the distribution of genotypes/subtypes of HCV in a group of patients with chronic hepatitis C from Canton Sarajevo during 2012-2018.Material and methods:The study enrolled 247 human plasma samples of HCV-RNA positive patients with available results of HCV genotyping test.Results: During 2012-2018, the domination of subtypes 1a (34.01%), 1b (28.34%) and genotype 3 (23.89%) was registered. In 2012 and 2013, HCV subtype 1a was the most common (27/63; 42.86% and 17/40; 42.50%, respectively). In 2014, the leading HCV genotype/subtype were 3 and 1b (17/57; 29.82%). In 2015, the dominance of HCV genotype 3 (14/39; 35.90%) continued, while in 2016, the same number of HCV subtypes 1a and 1b (11/30; 36.67%) was recorded. Although in a small number of tested, during 2017, HCV subtype 1b was the most prevalent (7/14; 50.00%), and in 2018, it was replaced by a HCV subtype 1a (3/4; 75.00%). Distribution of HCV genotypes/subtypes by age group of patients varied significantly (p=0.000). The largest number of patients (71/247; 28.74%) belonged to the age category 30-39 years and HCV genotypes/subtypes 1, 3, 4, 1a and 1b were identified. Except in 2017, male gender significantly dominated (p=0.000). In males, HCV subtype 1a (68/170; 40.00%) was the most common, while in women it was HCV subtype 1b (44/77; 57.14%).Conclusion: This six-year retrospective study showed the time variations of the circulating HCV genotypes/subtypes among patients with chronic hepatitis C in Canton Sarajevo. Genotyping of the HCV has an important implications for diagnosis and treatment of the patients.

Sign in / Sign up

Export Citation Format

Share Document